Are you Dr. Mobasher?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 40 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
# Stanford
Stanford, CA 94304Phone+1 650-723-7621Fax+1 650-723-6661
Summary
- Dr. Mehrdad Mobasher, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2007 - 2010
University of California (Irvine)Residency, Internal Medicine, 2004 - 2007
Tehran University of Medical Sciences School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2006 - 2026
Clinical Trials
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Start of enrollment: 2019 May 03
Publications & Presentations
PubMed
- 123 citationsSurvival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.Jason A. Zell, Pelin Cinar, Mehrdad Mobasher, Argyrios Ziogas, Frank L. Meyskens
Journal of Clinical Oncology. 2008-01-01 - 96 citationsVenetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason, Carla Casulo, Steven Le Gouill
Blood. 2019-05-02 - 568 citationsVenetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F. Seymour
The Lancet. Oncology. 2016-06-01
Press Mentions
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024October 16th, 2024- Advances in Oncology Clinical Trials and Hematology: The Impact of BTK InhibitorsSeptember 19th, 2024
- BRUKINSA® (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRAJanuary 19th, 2023
- Join now to see all
